Patient ‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial

ConclusionsBased on PSSD scores, greater improvements in symptoms and signs of psoriasis were reported by patients treated with guselkumab compared with placebo at week 16 or adalimumab through 48 weeks.This article is protected by copyright. All rights reserved.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fjdv.14910

Source: Journal of the European Academy of Dermatology and Venereology - March 6, 2018 Category: Dermatology Authors: K.A. Papp, A. Blauvelt, A.B. Kimball, C. Han, B. Randazzo, Y. Wasfi, Y. ‐K. Shen, S. Li, C.E.M. Griffiths Tags: Original Article Source Type: research